October 2016

Jochen H. Lorch, MD, MS discusses current approved treatment options for patients with MTC, the biology of the disease, managing potential progression, and future possibilities in the treatment of MTC.

With anaplastic thyroid cancer (ATC) being a rare disease that often has poor prognoses, researchers are seeking therapies for these patients that are more promising than surgery or radiation.

Early evidence suggests that the combination of locoregional therapy with an immune checkpoint inhibitor is a safe and effective strategy to pursue for patients with advanced hepatocellular carcinoma (HCC), according to a leading liver immunology expert.

Regorafenib has emerged as the clear choice for second-line therapy in advanced hepatocellular carcinoma (HCC) after demonstrating survival improvements for patients whose disease has progressed after systemic treatment, according to liver cancer experts.

David F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER® European Congress on Immunotherapies in Cancer held in Barcelona.

Ensartinib (X-396), a novel small-molecule tyrosine kinase inhibitor (TKI) developed to target patients with ALK-positive non–small cell lung cancer (NSCLC), demonstrated promising clinical activity in that subset of patients who are crizotinib (Xalkori)-naïve or crizotinib-resistant.

The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.

The Society for Immunotherapy of Cancer’s (SITC) Annual Meeting & Associated Programs are renowned as a catalyst for future advances in the cancer immunotherapy field. This year marks the 31st such conference (SITC 2016), which will be held in National Harbor, Maryland from November 9 to 13, 2016.

Resection of stage I lung adenocarcinoma can lead to 5-year survival rates of up to 87%, but whether adjuvant therapy can improve overall survival (OS) in this subset of patients is not yet clear.